Market Opportunities Use of GLP-1 Therapies in Metabolic Dysfunction and Development of Next-generation Oral & Combination Incretin Therapies Offer Growth Opportunities to Market Players The growing clinical potential of GLP-1 receptor agonists in treating MASH is creating significant opportunities for pharmaceutical manufacturers and biotechnology companies
From their beginnings as a treatment for type 2 diabetes, GLP-1 receptor agonists such as the semaglutide drugs Ozempic and Wegovy and the tirzepatide drugs Mounjaro and Zepbound have seen an explosion in use, most popularly for weight loss
Repeat customers receive better pricing, priority production scheduling, and more responsive technical support
Can children or teenagers take GLP-1 agonists
Through this mechanism, GLP-1RAs may reduce endothelial dysfunction and oxidative stress, both of which are key contributors to sepsis pathophysiology (57)
At JC Consulting, our life sciences recruitment consultants have years of experience helping Fortune 500 companies and startups expand into the Chinese market and connect with the right mid-to-senior-level talent to support their business needs
